Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
Morie A. Gertz, MD, chair, General Internal Medicine, Mayo Clinic Comprehensive Cancer Center, discusses the rationale for the phase 3 AFFIRM-AL trial (NCT04973137) in patients with amyloid light chain (AL) amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
myBinderRelated Content
-
Carpal Tunnel Syndrome May Triple Your Risk of Developing Stiff Heart SyndromeAccording to a recent study, carpal t...
-
Amyloid Pathology Transmission in Lab Mice and Historic Medical TreatmentsA UCL-led study has confirmed that som...
-
Doctors Making Progress in Treating AmyloidosisAmyloidosis is a rare condition that use...
-
Yvonne S. Eisele, PhDYvonne S. Eisele is Assistant Professor ...
-
Progress in Amyloidosis Research: Where Are We Now? – Webinarhttps://www.youtube.com/watch?v=8Yhv87Xo...
-
Intellia Therapeutics Call to Discuss Interim Clinical Data From NTLA-2001 Phase 1 StudyIntellia will present additional interim...
-
Alnylam Announces FDA Approval of AMVUTTRA™ (Vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropa...Alnylam Pharmaceuticals, Inc., the leadi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
